Emergent BioSolutions launches autoinjector to protect against chemical weapons attacks

Emergent BioSolutions ($EBS) just launched a military-grade intramuscular autoinjector device for self-administration of antidotes in the case of a chemical weapons attack. The device aims to provide militaries across the world with medical countermeasures to biological and chemicals threats. It has a needle that can penetrate not just skin, but soldiers' protective gear. The rollout of Emergard won't include the U.S., where the company intends to seek FDA approval. More from FierceMedicalDevices

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.